Integra LifeSciences Holdings Corporation logo

Integra LifeSciences Holdings Corporation

IART

NASDAQHealthcareMedical - Devices

Previous close

$16.74

+$0.15 · +0.90%

Aug 21, 4:00 PM ET

IART company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

63

Undervalued

Momentum

70

Gaining

Sentiment

64

Bullish

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Stuart Essig
Listed since
Aug 16, 1995
Employees
4,427

Market position

Day range

Current $16.74

52-week range

Current $16.74

Open
$16.81
Previous close
$16.59
Volume
551.8K
0.57× average
Average volume
973.79K
Average daily volume
Market cap
1.3B USD
Beta
1.21
Market reference 1
50-day average
$17.9878
-6.94% below average
200-day average
$13.5363
+23.67% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.75B USD
P/E (TTM)
-181.56×
P/B (TTM)
1.25×
P/S (TTM)
0.79×
EV / EBITDA
-8.43×
Earnings yield
-54.18%
Free cash flow yield
-4.75%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
53.74%
Operating margin
39.81%
Net margin
-0.44%
Return on equity
-49.50%
Return on assets
-14.34%
Return on invested capital
1.91%

Financial health

Debt / equity
1.94×
Current ratio
2.54×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends72%34%-3%-41%Gross margin, FY2021: 61.24%Gross margin, FY2022: 62.29%Gross margin, FY2023: 57.39%Gross margin, FY2024: 54.77%Gross margin, FY2025: 51.69%Operating margin, FY2021: 12.79%Operating margin, FY2022: 15.34%Operating margin, FY2023: 7.23%Operating margin, FY2024: 1.76%Operating margin, FY2025: 4.18%Net margin, FY2021: 10.96%Net margin, FY2022: 11.59%Net margin, FY2023: 4.39%Net margin, FY2024: -0.43%Net margin, FY2025: -31.58%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.24%. Gross margin FY2022 62.29%. Gross margin FY2023 57.39%. Gross margin FY2024 54.77%. Gross margin FY2025 51.69%. Operating margin FY2021 12.79%. Operating margin FY2022 15.34%. Operating margin FY2023 7.23%. Operating margin FY2024 1.76%. Operating margin FY2025 4.18%. Net margin FY2021 10.96%. Net margin FY2022 11.59%. Net margin FY2023 4.39%. Net margin FY2024 -0.43%. Net margin FY2025 -31.58%.

Income trends

Revenue

1.64B USD+1.53%

Operating income

68.32M USD+140.46%

Net income

−516.47M USD-7337.70%
Income trends across reported periods1.85B USD989.73M USD129.04M USD−731.65M USDRevenue, FY2021: 1.54B USDRevenue, FY2022: 1.56B USDRevenue, FY2023: 1.54B USDRevenue, FY2024: 1.61B USDRevenue, FY2025: 1.64B USDOperating income, FY2021: 197.23M USDOperating income, FY2022: 238.92M USDOperating income, FY2023: 111.53M USDOperating income, FY2024: 28.41M USDOperating income, FY2025: 68.32M USDNet income, FY2021: 169.08M USDNet income, FY2022: 180.55M USDNet income, FY2023: 67.74M USDNet income, FY2024: −6.94M USDNet income, FY2025: −516.47M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.54B USD. Revenue FY2022 1.56B USD. Revenue FY2023 1.54B USD. Revenue FY2024 1.61B USD. Revenue FY2025 1.64B USD. Operating income FY2021 197.23M USD. Operating income FY2022 238.92M USD. Operating income FY2023 111.53M USD. Operating income FY2024 28.41M USD. Operating income FY2025 68.32M USD. Net income FY2021 169.08M USD. Net income FY2022 180.55M USD. Net income FY2023 67.74M USD. Net income FY2024 −6.94M USD. Net income FY2025 −516.47M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.64B USD1.61B USD1.54B USD1.56B USD1.54B USD
Cost of goods sold790.01M USD728.47M USD656.84M USD587.36M USD597.81M USD
Gross profit845.23M USD882.06M USD884.74M USD970.31M USD944.64M USD
Research and development98.97M USD115.38M USD104.19M USD101.19M USD93.05M USD
Selling, general, and administrative699.7M USD716.98M USD656.64M USD616.32M USD637.45M USD
Operating expenses776.92M USD853.65M USD773.21M USD731.39M USD747.41M USD
Interest income18.47M USD20.04M USD17.2M USD11.92M USD6.74M USD
Interest expense86.26M USD70.63M USD51.38M USD49.59M USD50.4M USD
Depreciation and amortization151.05M USD140.5M USD123.51M USD121.12M USD123.67M USD
Operating income68.32M USD28.41M USD111.53M USD238.92M USD197.23M USD
Net income−516.47M USD−6.94M USD67.74M USD180.55M USD169.08M USD

Company facts updated Aug 24, 2026.

IART peers

ETFs holding IART

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research IART

research.disclaimer